Repositioning Candidate Details
| Candidate ID: | R1238 |
| Source ID: | DB09185 |
| Source Type: | approved; investigational; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Viloxazine |
| Synonyms: | 2-((2-Ethoxyphenoxy)methyl)morpholine; Viloxazine |
| Molecular Formula: | C13H19NO3 |
| SMILES: | CCOC1=CC=CC=C1OCC1CNCCO1 |
| Structure: |
|
| DrugBank Description: | Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) that was used in some European countries as an antidepressant drug. It structurally differs from conventional tri- or tetra-cyclic antidepressants and it does not produce sedative anticholinergic or adrenergic effects in man . While displaying amphetamine-like CNS stimulant effects, there is little evidence of drug dependence from viloxazine therapy. Viloxazine hydrochloride is a common active ingredient in drug formulation. It was discovered and brought to market in 1976 by Imperial Chemical Industries and in early 2000's, it was withdrawn from the market. |
| CAS Number: | 46817-91-8 |
| Molecular Weight: | 237.299 |
| DrugBank Indication: | Indicated for the treatment of clinical depression. |
| DrugBank Pharmacology: | Viloxazine is a selective noradrenaline reuptake inhibitor (NRI) with minimal inhibitory effect on the reuptake of 5-HT. It is also shown to upregulate the levels of GABA-B receptors in the rat frontal cortex. It is shown to form a complex with the human norepinephrine transporter (hNET) . The S(-)-stereoisomer of viloxazine exhibits more potent pharmacological actions . |
| DrugBank MoA: | Viloxazine inhibits noradrenaline uptake in rat and mouse heart tissue and has a weak effect on the uptake of 5-HT . In a docking study, the amino group of viloxazine points towards Asp75 in the drug binding pocket of the transporter and forms hydrogen bonds with Phe72, Asp75 and Phe317. The rest of the drug molecule forms hydrophobic interactions with other key residues in the binding pocket . |
| Targets: | Sodium-dependent noradrenaline transporter inhibitor |
| Inclusion Criteria: | Indication associated |
